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ABSTRACT 
Chronic myelogenous leukemia (CML), is a heterogeneous clonal myeloproliferative disorder, 
which occurs from the neoplastic transformation of the primitive hematopoietic stem cell. The 
presence of a balanced translocation t(9;22) (q34;q11), known as the Philadelphia (ph) 
chromosome which is the basis of the diagnosis and the hallmark of the treatment. The 
chromosomal translocation results in the reciprocal fusion of the BCR to the ABL gene to form 
the chimeric BCR-ABL gene. The respective oncoprotein (BCR-ABL) exhibits constitutively 
activated tyrosine kinase activity that is responsible for the activation of signal transduction 
pathways that lead to the abnormal bone marrow proliferation and to the clinical and 
morphologic manifestations of this unique leukemia. CML accounts for 20% of all leukemias 
affecting adults. Imatinib, which specifically inhibits the BCR-ABL kinase was first introduced 
into practice in 2001. Although it is established as a long term effective therapy for patients 
with chronic myeloid leukemia (CML), the research continues to advance on developing 
second generation tyrosine kinase inhibitors such as Dasatinib, Nilotinib. The current project 
has focused on computational analysis of protein kinase inhibitors that target the kinase domain 
of BCR-ABL which are structurally related to Imatinib. The protein kinase inhibitors was 
assessed for the inhibition property against CML from the Protein Data Bank (PDB). Total 53 
ligands were structurally optimized and docked against the CML target proteins BCR-ABL in 
Autodock vina. The ligand with significant higher binding energy compared to Imitinib were 
validated for drug likeness on ADMET toxicity screening tool. Intriguingly all the fatty acids 
showed docking energy in the range of -3.0 to -9.1 Kcal/mol. Among the different ligands, 
Alvocidib exhibited best affinity for the target as evident by the strong interaction with the 
target proteins in Ligplot. The in silico ADME results further substantiated the efficacy of 
Alvocidib showed as a potential natural source which could inhibit the tyrosine kinase activity 
of the BCR-ABL. 
 
Keywords: Chronic Myeloid Leukemia (CML), BCR-ABL, Protein Kinase Inhibitors, PDB, 
Ligands 
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CHAPTER 1: INTRODUCTION 
1.1 LEUKEMIAS 
Leukemia is a cancer of the blood-forming tissues characterized by the uncontrolled 
accumulation of immature white blood cells called "blasts" in the tissues of the body with or 
without a corresponding increase of those in the circulating blood. Leukemia is a broad term 
covering a group of diseases which have an effect on the blood, bone marrow, and lymphoid 
system, are all known to be hematological neoplasms [1]. 
Each year there are 351,000 new cases of leukemia worldwide which represent 2.8% of all 
cancers and 3.4% of deaths from cancer [2]. The number of people in the US are living with, 
or are in remission from, leukemia are estimated to 310046 [3]. It accounts for 30% of all 
cancers diagnosed in children under 15 years of age in industrialized countries [4].  
 
Tabele 1. Prevalence of leukemia. 
 
 
 
 
 
 
Approximate US Prevalence of the Four Major Types of Leukemia 
as of January 1, 2010 
Type Prevalence 
Acute Lymphoblastic Leukemia 66,030 
Chronic Lymphocytic Leukemia 119,386 
Acute Myeloid Leukemia 35,726 
Chronic Myeloid Leukemia 31,586 
Table 1. Source: Surveillance, Epidemiology, and End Results (SEER) 
Program (www.seer.cancer.gov). Prevalence database: “US Estimated 35-
Year L-D Prevalence Counts on 1/1/2010”. National Cancer Institute, 
DCCPS, Surveillance Research Program, Data Modeling Branch, released 
April 2013, based on the November 2012 SEER data submission. 
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Figure 1. Leukmia Classification 
 
Table 2. French-American-British (FAB) Classification of Acute Myeloid Leukemia (AML). 
FAB TYPE DESCRIPTION 
M0 Minimally differentiated AML 
M1 Myeloblastic leukemia with little maturation 
M2 Myeloblastic leukemia with maturation 
M3 Acute promyelocytic leukemia (APL) 
                                                       M3h APL, hypergranular variant 
                                                       M3v APL, microgranular variant 
M4 Acute myelomonocytic leukemia (AMML) 
                                      M4e0 AMML with dysplastic marrow eosinophils 
M5 Acute monoblastic leukemia (AMoL) 
                                     M5a AMoL, poorly differentiated 
                                      M5b AMoL, differentiated 
M6 Erythroleukemia 
                                     M6a AML with erythroid dysplasia 
                                      M6b Erythroleukemia 
M7 Acute megakaryoblastic leukemia (AMkL) 
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1.2 TYPES OF LEUKEMIA 
Leukemias can be classified in different ways based on the course of the disease and the 
predominant type of white blood cell involved. The most common types of leukemia are 
categorized in to four ways: 
1. Acute myeloid leukemia (AML) 
AML affects myeloid cells and grows quickly. About 18,000 new cases of this type of 
leukemia is enrolled each year. It occurs in both adults and children. AML is a common 
type of leukemia. AML is the most common type of acute leukemia in adults and affects 
males significantly more often than females.  
2. Acute lymphoblastic leukemia (ALL)  
ALL affects lymphoid cells and grows quickly. This is the most common type of 
leukemia in young children. Adults over the age of 65 are mainly affected by this type 
of leukemia. It accounts for more than 6,000 new cases of leukemia each year.  
3. Chronic myeloid leukemia (CML) 
CML affects myeloid cells and usually grows slowly at first. The abnormal blood cells 
work okay. It accounts for nearly 6,000 new cases of leukemia each year. It mainly 
affects adults. 90% of treated patients survive for over 5 years. A person with CML 
may have few or no symptoms for months or years before entering a phase in which the 
leukemia cells grow more quickly. 
4. Chronic lymphocytic leukemia (CLL)  
CLL affects lymphoid cells and usually grows slowly. The abnormal cells work almost 
as well as the normal white blood cells so it feels well for years without needing any 
treatment. It accounts for more than 15,000 new cases of leukemia each year. It almost 
never affects children, most often diagnosed patients are above age of 55. Over 60% of 
major patients with CLL are men. 75% of treated CLL patients survive for over five 
years. Experts say it is incurable. A more aggressive form of CLL is B-cell 
prolymphocytic leukemia.  
Each main type of leukemia is named according to the type of cell that's affected (a myeloid 
cell or a lymphoid cell) and whether the disease begins in mature or immature cells. The terms 
“myeloid” or “myelogenous” and “lymphoid,”“lymphocytic” or “lymphoblastic” denote the 
cell types involved. If the cancerous transformation occurs in the type of marrow that makes 
lymphocytes, the disease is called lymphoid, lymphocytic, or lymphoblastic leukemia. If the 
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cancerous change occurs in the type of marrow cells that go on to produce red blood cells, other 
types of white cells, and platelets, the disease is called myeloid, myelogenous, or myeloblastic 
leukemia. Based on how quickly the leukemia develops and grows it can be Acute, which is a 
rapidly progressing disease that results in the accumulation of immature, useless cells in the 
marrow and blood, or Chronic, which progresses more slowly and allows more mature, useful 
cells to be made. Adults can get either type; childen with leukemia most often have an acute 
type. Other types of leukemia and related disorders include: 
1. Hairy cell leukemia 
2. Chronic myelomonocytic leukemia (CMML) 
3. Juvenile myelomonocytic leukemia (JMML) 
1.3 CHRONIC MYELOID LEUKEMIA 
Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a 
heterogeneous clonal myeloproliferative disorder, which occurs from the neoplastic 
transformation of the primitive hematopoietic stem cell. It is a type of leukemia that is 
characterized by increased proliferation of the granulocytic cell line without the loss of their 
capacity to differentiate. It accounts for 20% of all leukemias affecting adults with an estimated 
5920 new cases and 610 deaths due to this disease in the United States (US) in 2013 [34].  
The pathologic hallmark of this disease is the Philadelphia chromosome which is observed in 
about 90% of CML patients [37]. The disease is associated with a chromosomal abnormality, 
this genetic abnormality results from translocation of ABL1 from chromosome 9q34 with the 
breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known 
as the Philadelphia chromosome. The molecular consequence of this translocation is the 
generation of a BCR-ABL fusion oncogene, which in turn translates into a BCR-ABL 
oncoprotein. The respective oncoprotein (BCR-ABL) exhibits constitutive activated tyrosine 
kinase activity that is responsible for the activation of signal transduction pathways that lead 
to the abnormal bone marrow proliferation and to the clinical and morphologic manifestations 
of this unique leukemia [36]. CML can be divided into three phases: the chronic phase (CP), 
the accelerated phase (AP), and the blast phase (BP) that resembles acute leukemia. 
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1.4 PHILADELPHIA CHROMOSOME 
 
Figure 2. Locations of the breakpoints in the ABL and BCR genes and structure of the 
chimeric mRNAs derived from the various breaks Locations of the breakpoints in the ABL 
and BCR. 
 
Figure 3. The t(9;22) Translocation and Its Products: the BCR-ABL Oncogene on the Ph 
Chromosome and the Reciprocal ABL-BCR on the Derivative 9q+ Chromosome. 
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The translocation between chromosomes 9 and 22 t(9;22)(q34;q11) or its variants t(V;9;22) 
[1]. This reciprocal translocation generates the shortened 22q known as the Philadelphia (Ph) 
chromosome and the new fusion oncogene is called as BCR-ABL (Breakpoint Cluster Region-
Abelson Leukemia). This oncogene encodes a chimeric 210 KD BCR-ABL protein that 
incorporates an activated ABL tyrosine kinase domain. The constitutive activity of this tyrosine 
kinase plays a central role in the pathogenesis of the disease. The expression of chimeric BCR-
ABL protein with deregulated tyrosine kinase activity has been shown to be necessary and 
sufficient for the trans-formed phenotype of CML cells. Most of the CML patients have been 
diagnosed in chronic phase (CP), but as a result of genomic instability, it progresses to ill-
defined unstable accelerated phase (AP) and then to the terminal blastic crisis phase (BP) over 
time, becoming increasingly resistant to therapy. 
1.5 MECHANISM OF BCR ABL SIGNALLING PATHWAYS 
Figure 4. Signal Transduction Pathways Affected by BCR-ABL. 
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1.5.1 RAS-RAF-MAPK-ERK PATHWAY 
Leads to the activation of gene transcription and Ras activation is important for pathogenesis 
of Ph-positive leukemias. 
1.5.2 MYC PATHWAY 
On the cellular context, Myc constitutes a proliferative or an apoptotic signal. The apoptotic 
arm of its dual function is counterbalanced in CML cells by other mechanisms, such as the 
Phosphatidilinositol-3-kinase (PI3k) pathway. 
1.5.3 PHOSPHATIDILINOSITOL -3-KINASES (PI3KS) PATHWAY  
PI3 kinase activity is required for the proliferation of BCR-ABL positive cells. The final 
process potentially induces more efficient degradation of p53 through p110. 
1.5.4 JAK-STAT PATHWAY 
STAT5 functions as a transcription factor. The activation of STAT5 by p210 BCR-ABL 
induces malignant transformation of the K562 cell and inhibits apoptosis by up regulating the 
transcription of BCL-XL. 
1.5.5 CYTOSKELETON PROTEINS 
The function of β-integrins on the surface of CML cells is abnormal and the final effect is 
reduced adhesion and increased proliferation. 
1.5.6 TRANSFORMATION 
The BCR-ABL abrogates cell dependence on external growth factors by up-regulating 
interleukin production and alters the cell adhesion properties by modulating the expression and 
activation of focal adhesion kinase and other proteins. 
1.6 OBJECTIVE 
 To explore the agents that are linked to BCR-ABL and its receptors, central to 
transduction pathways responsible for CML. 
 To identify the ligands from the pool of protein kinase inhibitors of BCR-ABL with 
structural similarity to Imitanib by binding energy estimation. 
 To analyze the suitability of the novel inhibitors as drugs against CML by ADMET 
studies. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 THERAPEUTIC OPTIONS CML 
Table 3. Currently available Therapies for Chronic Myeloid Leukemia. 
 
AGENT/THERAPY 
 
CLASS OF AGENT 
 
EFFECT ON DISEASE 
Hydroxyurea Antimetabolite Rapid cytoreduction 
Interferon alfa Immune modulator 10%–38% major cytogenetic response, 
Lessening of effect over time, 
Safe during pregnancy 
Imatinib Tyrosine kinase 
inhibitor (TKI) 
Now treatment of choice;  
70% long-term disease control at molecular level 
Dasatinib, nilotinib Second generation TKI Mostly used as second-line therapy in imatinib 
failure or intolerance 
Allogeneic bone 
marrow transplantation 
Not applicable Remains the only known cure; 
Generally now reserved for TKI failure 
 
2.1.1 NON-TARGETED THERAPY 
Busulphan or hydroxyurea were treated in the chronic phase (CP) of the disease in over 80% 
of patients. In CP, generally the median survival was 35 to 65 months. Before the development 
of blastic phase (BP) starts, two thirds of patients will progress to the accelerated phase (AP). 
The median survival for patients with AP is 1 to 2 years and for BP patients is 3 to 12 months. 
But when patients are treated with interferon (IFN), severe toxicities and reduction in efficacy, 
persistence in CP disease and progression are mainly associated with it. So in this treatment 
the median survival of patients was 65 to 90 months and complete cytogenetic responses 
(CCgR) at rates of 5 to 20% in early CP CML [5]. In the CML 91 trial 325 patients were 
included in the period of 1991 to 1996 and compared with 553 patients in the Imatinib (IRIS: 
International Randomized Imatinib Study ) group between 2001 to 2002. Both groups of 
patients, showed CCgR, survival free of transformation for a follow-up of 42 months. Overall 
survival rates were considerably higher with Imatinib compared than with IFN/Ara-C (p<.001, 
p= .004, and p<.001 respectively). So this historical comparison is relevant because the survival 
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benefit in the IRIS study for IFN/Ara-c could not be evaluated due to the high crossover rate 
to the Imatinib group. Allogeneic stem cell transplantation is a potential curative for leukemia 
although it is limited by suitable donor availability and transplant associated mortality and 
morbidities. 427 abstract were presented in a randomized study of 621 new patients in CP Ph+ 
with a follow-up of 8 to 9 years. The result form this follow up is that, those patients who are 
treated with the best available drug treatment (first treated with INF alpha and Gleevec 
thereafter) the median survival was 73%. But the median survival is 62% for those who are 
treated with allogeneic stem cell transplant (p=0.049). From this experiment they concluded 
that in particular for those patients with low risk 85% vs. 68% respectively, Drug treatment is 
superior to hematopoietic stem cell transplantation (HSCT) in patients with CP CML. 
Transplant related mortality (26.1%) is reflected by inferior survival rate in the transplant group 
[7]. 
 
2.1.2 TARGETED THERAPIES 
The most important basis of the pathophysiology of the CML is the understanding of the 
signaling molecular pathways of the BCR-ABL cells which was the hallmark of new drug 
research. All cellular events are governed by signal transduction events that depend on highly 
coupled intracellular networks of specific protein-protein interactions, which are, in turn, 
functionally controlled by reversible phosphorylation reactions catalyzed by protein kinases. 
Accordingly, Tyrosine kinases play principal role in initiation of signal transduction pathways 
in CML. The common feature preserved in protein kinase family is the catalytic domain with 
its associated catalytic center. Almost all proteins kinases employ ATP as a co substrate in 
order to transfer the gamma-phosphate of ATP onto an acceptor protein, peptide or lipid 
substrate [8]. The chimeric oncogene BCR-ABL that is generated by the fusion of BCR and 
ABL is not found in normal cells. The respective oncoprotein BCR-ABL, which exhibits 
constitutively tyrosine kinase activity leading to excessive cell proliferation. The drugs that 
inhibit BCR-ABL activity known as tyrosine kinase inhibitors (TKIs) are mainly the standard 
cure for CML. These drugs are expected to act as targeted therapy as they don’t affect normal 
cells. So they don’t have severe side effects as seen with other drugs which are used for 
treatment of CML like Traditional chemotherapy drugs or interferon. But it is of great 
importance of understanding that if the TKIs are taken during pregnancy, they can harm the 
fetus. TKIs appear as the best drug against chronic phase CML, but there are other newer drugs 
which can treat patients with more advanced disease [10].  
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2.1.2.A Imatinib 
In a program involving investigation of the development of specific TKIs, Imatinib or STI571 
[signal transduction inhibitor, (formerly known as CGP 57148B)] was generated [9]. Imatinib 
is a 2-phemylamino-pyrimidine, which is an oral administered drug and exhibits tyrosine 
kinase inhibition once a day. The BCR-ABL protein which signals the body to proliferate too 
many WBCs is inhibited by Gleevec by binding to the kinase domain of the receptor. It blocks 
the pathway initiated by BCR ABL and stops the overproduction of WBCs. It was revealed 
that the cellular proliferation and apoptosis induction of BCR-ABL CML and ALL cells lines 
are blocked by the drugs activity. Normally tyrosine kinase helps to stimulate the growth of 
cancer cells. Blocking tyrosine kinase reduces the production of abnormal white blood cells. 
Gleevec turn out to be the first standard cure for CML patients as it particularly inhibiting the 
BCR-ABL protein. As it was the first TKI drug used against CML, so it is called as first 
generation TKI. In some patients, imatinib resistance occurs in which the drug ultimately stop 
working. Resistance occurs due to the formation of mutation gene from the normal gene which 
can be overcome by dose enhancement. But sometimes patients have to shift to other drugs 
which are of grater potency like 2nd generation TKIs. As it slows the development of the 
leukemia and prevent the condition reaching to AP phase so it is given on completion of 
diagnosis [10]  
2.1.2.B Nilotinib 
Nilotinib (AMN107, Tasigna™; Novartis) is discovered by the incorporation of an amide (N- 
methylpiperazine) moiety into imatinib to enhance its solubility and oral bioavailability. 
Replacement of the amide moiety with alternate binding groups and also retaining hydrogen 
bond interactions to Glutamine286 and Aspartase381, led to the formation of a more potent 
structural derivative of imatinib which is an amino pyrimidine [11]. This drug binds to the 
inactive conformation of the kinase domain of BCR-ABL protein, with a 25-fold increase 
potency as compared to Imatinib molecule. It mainly targets the most resistance shown by 
mutational change of gene in imatinib treatment except T315I mutation. PDGFR (Platelet 
Derived Growth Factor Receptor) and c-Kit are inhibited by the activity of nilotinib drug but 
have no effect on Src kinases [12-14]. Hematologic and cytogenetic responses were noted as 
89% and 50% respectively in CP CML patients that are resistant to imatinib treatment. The 
response rates are dependent on drug dosage of nilotinib which is generally 400mg twice a day. 
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Accelerated, myeloid and lymphoid blastic phases of CML were also promised to have a 
positive effect in patients by this results [15-18]. 
2.1.2.C Bosutinib 
Bosutinib is one of the most capable drugs among other second line treatments available for 
CML. It was found that Bosutinib is more effective than imatinib, and it can overcome several 
number of mutations that reduce CML resistant to imatinib. Although bosutinib is better than 
many other existing treatments for CML, it is may not be effective for all patients. The T315I 
point mutation which can developed by BCR-ABL protein in CML renders resistant to 
imatinib, bosutinib, and other TKIs. Bosutinib is effective against the patients, those were 
treated by the first and second generation TKI and shown resistance to the treatment, as it is a 
3rd generation TKI. Unlike imatinib, Both ABL and Src kinases autophosphorylation are 
inhibited by bosutinib, and resulted in reticent of cell proliferation and apoptosis. So this drug 
is approved by Food and Drug Administration in United States for the treatment in chronic, 
accelerated, or blast phase in patients resistant or intolerant to other TKIs. 
2.1.2.D Dasatinib 
Some of the multi-target kinase inhibitors of BCR-ABL, ephrin receptor kinase, SFK and 
PDGFR is Dasatinib (BMS-354825, Sprycel; Bristol Myers Squibb). Dasatinib is not related 
to Imatinib in structure. Dasatinib is a thiazolecarboxamide. Dasatinib has the capability of 
binding to both active and non-active conformational sites of ABL kinase domain. In addition 
to that this molecule can inhibit Src kinase which targets different tumor progressive pathways 
relative to that of Imatinib molecule [19]. Research says that Dasatinib have 325 fold of 
increased potency as compared to Imatinib and capable of harboring potent inhibitory activities 
against Imatinib resistance mutant tests [20]. Sprycel is a TKI (Tyrosine Kinase Inhibitor) 
which targets BCR ABL protein. It is also called as second generation of TKI as it comes after 
Imatinib. Sprycel is an oral bio-available drug. Dasatinib is used as the drug for initial treatment 
for CML; it acts as a replacement drug for patients who can’t take Imatinib as a drug for CML. 
During the approval of this drug it was said to take twice a day as a pill, but more often larger 
dose is preferred for a single day. Dasatinib more often inhibit CrkL phosphorylation and result 
in reduction of total number of CD34+CD38– CML cells as compared to Imatinib. 
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2.1.2.E Omacetaxine Mepusuccinate 
Adult patients with more than one resistance or intolerance history while earlier therapies 
(tyrosine kinase inhibitors) are recommended Synribo or Omacetaxine Mepusuccinate. It is 
generally administered subcutaneously and is found effective in patients with history of 
multiple tyrosine kinase inhibitor failures. It is injected subcutaneously and is effective in 
patients with multiple tyrosine kinase inhibitor failures, also with the T315I mutation. Synribo 
was approved on the basis of the responses of the volunteers during the trial. The patients were 
both in chronic and accelerated phase. The data for long term survival is still being accrued. 
2.1.2.F Interferon Alpha 
Interferon is one of a kind of biological therapy that can execute well for chronic phase CML. 
It is usually can be used in the following situations; 
 If other types of biological therapy do not work or stop working after a while 
 If other types of biological therapy cause too many side effects 
 If you had a bone marrow or stem cell transplant but your CML comes back. 
About 1 out of 5 people shows such responses that are so good that there are no longer any 
Philadelphia chromosome positive cells present in their bloodstream or bone marrow. Usually 
this response is long lasting and sometimes it works for 10 years or more. Usually people carry 
on with the interferon for 2 or 3 years at the least. Interferons have various side effects but these 
side effects vary a lot in different people. Some people don’t have any or a little trouble with 
interferon. Others face various troubles with interferons. Some of the most common side effects 
of this are flu like reaction, with aching muscles, a high temperature and weakness. In these 
situations Paracetamol usually helps. Some people may also feel nauseating and lose their 
appetite. 
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2.1.2.G Ponatinib 
Ponatinib is a second generation tyrosine kinase inhibitor targeting BCR-ABL, so it is used in 
patients with CML after the treatment with another TKI. When the drug resistance appears in 
patients due the mutation of the gene, it is effective than other TKIs. The mutation developed 
due to the treatment of TKI in some patients, is known as T315I mutation. First generation 
TKIs are ineffective against this type of mutation. But ponatinib is the first potent tyrosine 
kinase inhibitor which remains effective against all other known BCR-ABL permutations and 
target T315I point mutation in CML. In spite of side effects as other TKIs, it remains as a 
promising drug in the treatment of CML by targeting the intractable T315I mutation. Ponatinib 
was recently approved by Food and Drug administration in United States as a second line cure 
for CML in patients who have shown resistance to multiple other TKIs due to its effectiveness 
against T315I mutated BCR ABL. It is an oral bioavailable drug prescribed to take a pill once 
a day. 
2.1.3 BONE MARROW AND STEM CELL TRANSPLANTS  
Long term remission in CML can only achieved by bone marrow or cord blood transplant 
(BMT) of stem cells from a related or unrelated donor. Stem cells of different organisms are 
involved in this type of treatment so these types of transplants are known as allogeneic 
transplants. Another type of transplant, in which patient’s own cells are used in the bone 
marrow transplantation is known as autologous transplant. These are hardly ever used in the 
treatment of CML. High dose chemotherapy is given to the patient to kill the cancerous cells 
already present before the bone marrow transplantation. Then the bone marrow of patient is 
infused and repopulated with the transplant cells. A sibling or a twin is often the best match. 
Bone marrow transplants are prone to risks and side effects and potential complications. In 
most cases of chronic leukemia especially among elderly patients, the potential risks of 
transplantation far outweigh any benefit. The risks associated in this treatment are; 
 Graft versus host disease (GVHD). 
 Veno occlusive disease. 
 Life threatening infections. 
 Risk of secondary malignancies. 
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CHAPTER 4: MATERAILS AND METHOD 
 4.1 TOOLS USED 
 Marvin Sketch - For drawing Novel Ligand/Inhibitor  
 Online Translator - For Translating ligand file format to pdb  
 PDB - For Downloading Receptor/Protein .pdb files  
 Corina- To conver 2d ligands to 3d 
 Arguslab softaware- For cleaning and minimization  
 Pubchem – Database of inhibitors 
 Prodrg Server- Energy minimization of  inhibitors 
 Chimera - For Visualization and Energy Minimization studies 
 Openbabel- To convert to different formats 
 Pymol – For visualization and alignment 
 Auto Dock 4 - Potential offline Docking(protein+ligand) tool widely used  
 Autodock vina - Docking without grid box 
 Ligand scout - To find the specific interactions 
 Lig plot – To find out  atomic interactions 
 FAF-DRUG- To check drug likeness 
4.2 RETRIEVING RECEPTORS FROM PDB 
 Open Protein data bank, rcsb.org. 
 Type receptor name in search i.e. BCR-ABL.  
 Retrieve the pdb (3CS9) files of the receptors and store them in pdb.text file format for 
further use.  
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Figure 5. Snapshot of Protein Data Bank webpage with BCR-ABL receptor (PDB ID: 3CS9). 
 
Figure 6. 3D view of 3CS9 (Human ABL kinase in complex with nilotinib) in Jmol_S. 
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Figure 7. Snapshot of amino acid sequences of 3CS9 in UniProt. 
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4.3 RETRIEVING LIGANDS FROM PUBCHEM AND CONVERSION TO 
PDB FORMAT BY  
 
Figure 8. Snapshot of Corina Online 3D Generation webpage. 
4.3.1 CORINA 
If the inhibitor is in 2d format, then convert it to 3d in corina by the following steps [23]: 
 First open the corina online converter webpage by entering “http://www.molecular-
networks.com/online_demos/corina_demo_interactive” in the address bar. 
 Then enter the ligand in the .sdf or .mol format by right clicking on the left hand side 
corina window. 
 After submitting the ligand, corresponding 3d molecule will be generated on the right 
hand side of window. 
 We can download the 3d generated molecule in either .pdb or .mol format. 
4.3.2 OPEN BABEL 
 Open pubchem by entering pubchem.ncbi.nlm.nih.gov in the address bar of the search 
engine. 
 In search type the name of inhibitor & enter. 
 All the available ligands will appear, if something is missing search for the same in           
chemspider.  
 Save the 3D .sdf format of the ligands from pubchem and chemspider.  
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 Give the above .sdf format in open babel software as input by browsing the file from 
computer and convert it to the .pdb format by selecting the output format.  
 Now the pdb format ligand is in 3D structure that will be used in following steps.  
4.4 ENERGY MINIMIZATION OF LIGANDS 
Before binding energy is being calculated, structural inconsistencies are first corrected, by 
adding hydrogen atoms and associated atoms with parameters of force field. Energy 
minimization is used to compute the equilibrium configuration of ligand. It makes the ligand 
flexible so that ligand can properly orient itself on the receptor during docking. Energy 
minimization was done by PRODRG, an online server following the given steps-  
4.4.1 PRODRG SERVER 
 Open Prodrg beta server.  
 Paste the pdb format of ligand in the space provided & run Prodrg.  
 Save the energy minimized pdb file (all hydrogens) generated by the server for future 
use.  
 
Figure 9. Snapshot of PRODRG server (online minimization page). 
4.4.2 ARGUS LAB SOFTWARE 
 Open the Argus lab software by double clicking on it. 
 Open the ligand from file         open, then select the ligand.pdb molecule from the 
computer. 
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 From Calculation         Optimize Geometry, then a new window will pop up. 
 Select UFF in Molecular Modelling (MM) of Hamiltonian window and Steepest 
Descent in Line Search of Geometry Search window. 
 Then set Maximum Steps Taken as 1 lakh and click ok. 
 After sometime the result should appear as “Geometry Optimization Converged”. 
 Then save the molecule as pdb. 
 
 
Figure 10. Snapshot of Energy minimization in Argus Lab software. 
 
4.5 ENERGY MINIMIZATION OF RECEPTOR 
The receptors obtained from the Protein Data Bank are generally complex files i.e., NMR 
structures of already docked receptor with some existing inhibitors. For using the same receptor 
for our docking studies, the receptor should be cleaned by eliminating the existing ligand and 
water molecules. The reactive groups created by removing this ligand should be substituted 
with hydrogens. For the cleaning of receptor Argus lab software has been used and for removal 
of the ligands CHIMERA has been used. The resultant PDB structure can be saved. The 
following steps are followed-  
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4.5.1 ARGUSLAB SOFTWARE 
 Open the ArgusLab software by double clicking on it. 
 Open the receptor file from File          Open, select the molecule by browsing the 
computer. 
 View the molecule hierarchy wise then delete the water and miscellaneous molecules 
from residues. 
 Then save the molecule as pdb. 
 
Figure 11. Snapshot of Receptor Cleaning in Argus Lab software. 
4.5.2 CHIMERA 
 Double click chimera open receptor file. 
 Select           Structure           ligand. 
 Delete the selected ligand from Action         Delete. 
 Save the resultant file in pdb format and use for docking. 
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Figure 12. Snapshot of CHIMERA (Ligand Removal). 
 
4.6 DOCKING BY AUTODOCK VINA 1.1.2 
Docking is a method which predicts the binding affinity of a small molecule (ligand) with a 
larger molecule (receptor) when bound to each other to form a stable complex. Each docking 
program utilizes a unique scoring function to rapidly approximate properties such as receptor 
ligand binding. Autodock is a docking tool based on a linear regression analysis  of free energy 
scoring function of how small a molecule is and the AMBER force field that occur between a 
ligand and protein target. It has an enhanced version i.e. Autodock Vina with an improved local 
search routine allowing the usage of multi-CPU or multicore computer setups. Autodock Vina 
is a modeling software for molecules and their structural simulation which is effective 
for docking. It is one of the most cited open-source program for doing molecular docking in 
the research community. Auto docking is a research centers for FightAIDS@Home project 
which is operated by World Community Grid [22].  
The introduction of Autodock vina is due to the following features: 
 It improves the average accuracy of binding predictions of molecules as compared to 
Autodock 4. 
 In orders of magnitude, it is faster than AutoDock 4. 
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 Capable in reducing operation time, when operated in multiple CPUs or CPU cores on 
system. 
After preparing the protein and ligand files through chimera and Argus lab software, all files 
must be kept in a single folder. Further modification to the protein and ligand, something like 
fixing the torsion residues etc. are made and the files are saved in PDBQT format. The conf.txt 
was prepared by putting the required grid size and coordinates of the active site. After docking 
completes, the results are saved in a file named log.txt in the folder.  
4.6.1 PREPARATION OF PDBQT FILES  
AutoDock 4 uses PBDQT file format for docking purpose. PDBQT files can be generated and 
viewed using MGL Tools. It acts as the input and output files as lock and key. The files are 
prepared for both ligand and receptor. Here the PDBQT files are generated in Autodock 4. 
Receptor: 
 Open the autodock 4 software by double clicking on it. 
 From file         Read molecule          then choose the receptor molecule after cleaning 
from the computer. 
 From Edit         Atoms          Assign AD4 type 
 Again from Edit         Charges          Add Kollman Charges and repeat the step for 
Compute Gasteiger.  
 Edit         Hydrogens        Add         A new window will pop up and set the parameters 
as the default, then press Ok. 
 From Grid         Macromolecule         Choose, then a new window will appear, select 
the receptor molecule and press ok. 
 After pressing ok, save the molecule as receptor.pdbqt appeared on the new window. 
Ligand:  
 Open the autodock 4 software by double clicking on it. 
 From file         Read molecule         then choose the ligand molecule after energy 
minimization from the computer. 
 From Ligand          Input         Choose, then a new window will appear, select the ligand 
molecule and press ok. 
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 From Ligand         Torsion Free         select Choose Root and repeat the same step for 
Detect Root. 
 From Ligand         Output        Save as Pdbqt. 
After preparation of the pdbqt files, the files are kept in a single folder in which other pdb files 
are kept and the docking procedure starts.  
Docking Command: 
For docking five files (i.e conf.txt, ligand.pdbqt, ligand.pdb, receptor.pdbqt and receptor.pdb) 
are required in a single folder and the steps are given below:  
 Start the computer          click start menu         type cmd in the search menu in windows 
7. 
 Asses the folder in which the files are kept by giving the required command (cd c:\vina). 
 Open the folder of the installed autodcok vina from program files(x86) from the 
computer. 
 Then drag the vina.exe file to the command prompt menu from the vina folder of The 
Scripps Research Institute folder. 
 Give the command as “ __config conf.txt __log log.txt” to run the operation. 
The steps followed for docking are mentioned below-  
 Get the receptor (3CS9) coordinates (i.e. 22.328, 47.929, and 105.134) from the PDB 
by opening the pdb file in word and noting down the coordinates in the position of 
363(Active site in uniprot id-P00519).  
 Clean the receptor and remove the ligand.  
 Add hydrogen atoms or residual atoms and minimize the receptor.  
 Get the minimized ligand from PRODRG server or Argus lab software.  
 Prepare the docking suitable files for LOCK and KEY (pdbqt files).  
 Prepare the needing files for docking (conf.txt).  
 Run the docking.  
 Get the docking results from the file log.txt.  
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Conf.txt generation: 
The contents of a sample conf.txt file are: 
receptor = 3cs9.pdbqt 
ligand = ligand.pdbqt 
center_x = 22.328 
center_y = 47.929 
center_z = 105.134 
size_x = 126 
size_y = 126 
size_z = 126 
out = all.pdbqt 
The grid center coordinates are (22.328, 47.929, 105.134). 
 
4.7 ANALYZING DOCKING RESULTS 
Primarily the results of AutoDock can be analyzed based on the best and lowest binding 
energies stored as a table in conf.txt file (Docking Log file). This file can be opened using text 
editor and can be investigated for the binding energy values. The interactions of the ligands 
with different amino acid residues of the receptor can found in detail by analyzing the 
complex.pdb using ligplot. Pymol is used for the preparation of the complex.pdb file but later 
interaction can be visualized by pymol in ligplot. 
4.7.1 PYMOL 
 Convert the all.pdbqt output file from vina folder to .pdb file format and save it. 
 Open the all.pdb file from the folder in pymol viewer by browsing from the computer. 
 Again open the receptor (3cs9.pdb) file in pymol from the vina folder. 
 Now we can see the 9 posed positions of the receptor and the complex structure. 
 Save both file as .pdb by going to file and clicking on save molecule. 
4.7.2 LIGPLOT 
 Lunch ligplot software. 
 Open complex file which is saved by pymol viewer. 
 Go to file and browse the file and click ok to view the interaction. 
 Then a new window will ask the permission of running the ligplot for operation of 
visualization. 
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Figure 13. Posed position of the complex structure with receptor. 
 
 
Figure 14. Atomic interactions of BCR ABL with CID 4616292. 
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Figure 15. Atomic interactions of BCR ABL with CID 5287969. 
 
Figure 16. Atomic interactions of BCR ABL with CID 72271. 
28 | P a g e  
 
4.8 ADMET STUDIES  
The success of a drug depend on its ADME (Absorption, Distribution, Metabolism and 
Elimination) characters in the body. The early prediction of ADME toxicity for drug likeness 
of a new ligand helps in reducing the probability of its failure at the drug development stage. 
Thus, In silico analysis like ADME prediction, Molecular descriptors calculation, Drug 
likeness prediction, Drug toxicity prediction can be done by the PreADMET tool. The steps 
involved in ADMET studies are as follows-  
 Open FAF-Drugs homepage by typing: http://bioserv.rpbs.univ-paris-diderot.fr/FAF-
Drugs/ 
 Then click on run FAF-Drugs option below. 
 A new window will pop up. Then submit the .sdf file of the ligands for analysis by 
clicking upload menu in the new window. 
 XLOGP3 was set as logP computation program.  
 Rests of the filtering options were kept as default. 
 Then click on the run button to start the processing.  
 After the processing the overview page will open. Click on full screen to get the result 
of the drug. 
 Click on ligand id, then tabular result will open, there we can analyze the Drug likeness, 
ADME and Toxicity of the ligand from the different images. 
Pharmacokinetic properties of the protein kinase inhibitors were predicted by using FAF-
Drugs2 server. ADME-Tox prediction helps in differentiating drug non like and drug like 
properties of docked molecules and predicts high probability of drugs failure or success rate 
due to its toxicity. This early in silico prediction helps in early preclinical assessment and 
thereby avoiding costly late stage preclinical and clinical failures [21]. 
ADMET Profiling can be categorized into ways; 
1. Oral Bioavailability: Lipinski RO5, Veber Rule, Egan Rule, Bayer Oral Physchem 
score 
2. Drug Safety Profiling: GSK 4/400 Rule, Pfizer 3/75 Rule, Phospholipidosis, Lilly 
MedChem Rules 
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Figure 17. FAF-Drug server home page. 
 
Figure 18. Snapshot of physico-chemical property filters used in FAFDrugs2 server. 
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CHAPTER 5: RESULT AND DISCUSSION 
5.1 RESULTS OF DOCKED INHIBITORS 
Drug bank (Pubchem) is the source of newly synthesized molecules with unknown activity. 
We have downloaded a total 53 protein kinase inhibitors, structurally similar to Imatinib from 
drug bank for docking with BCR-ABL receptor. The Ligands and the receptors were retrieved 
and minimized as a preparatory step for Docking. Molecular Docking of ligand inhibitors are 
performed using Autodock vina. The BCR-ABL receptor is docked with the imatinib analogues 
which gave binding energy in the range of -3 to -9.1 Kcal/mol. The docking results are 
compared with a control drug Imatinib of binding energy of -8.2 Kcal/mol. Then the ligand are 
screened on the basis of their docked binding energies which is given in the Table. 4.  
The results of binding affinity of 53 ligands with the receptor are tabulated below- 
 
 
Table 4. Docking results of 53 Drug bank molecules with BCR ABL. 
 
SL NO 
 
LIGAND ID 
 
BINDING ENERGY(-Ve) (Kcal/Mol) 
1 CID 71300928 6.2 
2 CID 56603728 7.2 
3 CID 56671814 7.7 
4 CID 51340302 7.4 
5 CID 46908927 7.9 
6 CID 22386467 8.3 
7 CID 16760499 6.8 
8 CID 16219471 6.9 
9 CID 11957580 6.5 
10 CID 11957465 6.0 
11 CID 11679357 5.6 
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12 CID 11626560 7.5 
13 CID 11557040 1.6 
14 CID 9941095 6.4 
15 CID 9910986 7.5 
16 CID 9886292 7.8 
17 CID 6858240 6.0 
18 CID 5702541 7.0 
19 CID 5702541 6.7 
20 CID 5329098 8.0 
21 CID 5312122 7.6 
22 CID 5287969 9.1 
23 CID 5280961 6.4 
24 CID 5235506 7.8 
25 CID 4616292 9.1 
26 CID 3078519 7.4 
27 CID 3062316 6.9 
28 CID 3035414 5.3 
29 CID 449241 6.8 
30 CID 406563 6.9 
31 CID 312145 7.2 
32 CID 216239 8.6 
33 CID 208909 1.9 
34 CID 208908 7.8 
35 CID 176871 7.0 
36 CID 176870 6.5 
32 | P a g e  
 
37 CID 163751 6.6 
38 CID 160355 7.2 
39 CID 151194 7.3 
40 CID 151193 4.0 
41 CID 123631 8.2 
42 CID 123596 3.3 
43 CID 108152 7.4 
44 CID 72271 9.1 
45 CID 5291 8.2 
46 CID 3843 8.4 
47 CID 3547 7.2 
48 CID 3546 6.5 
49 CID 3544 5.9 
50 CID 3499 8.6 
51 CID 3220 7.4 
52 CID 3134 4.8 
53 CID 1352 7.0 
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Table 5. Ligand Screened for further ADMET studies. 
SL 
NO 
PUBCHEM ID LIGAND 
NAME 
Binding Energy(-Ve) 
(Kcal/Mol) 
 
1 
 
CID 72271 
 
7-hydroxystaurosporine(UCN-01) 
 
9.1 
 
2 
 
CID 5287969 
 
Alvocidib 
 
9.1 
 
3 
 
CID 4616292 
 
7-hydroxystaurosporine(UCN-02) 
 
9.1 
 
4 
 
CID 216239 
 
Sorafenib 
 
8.6 
 
5 
 
CID 3499 
 
Go 6983 
 
8.6 
 
6 
 
CID 3843 
 
KT 5823 
 
8.4 
 
7 
 
CID 22386467 
 
Vatalanib 
 
8.3 
 
8 
 
CID 123631 
 
Gefitinib 
 
8.2 
 
9 
 
CID 5291 
 
Imatinib(Control drug) 
 
8.2 
 
5.2 PreADMET RESULTS 
Based on the binding energy of inhibitors with BCR ABL and structure of the compound, 9 
ligands are selected for ADMET studies to know their Molecular descriptions, Drug Likeness, 
ADME data, Toxicity. Out of 9 inhibitors only 3 qualified as drug. But CID 72271and CID 
4316292 are two molecules of same molecular weight with different structure as these are 
imatinib related protein kinase inhibitors so we are taking CID 72271 in to consideration. The 
results and the properties of the different ligands are shown below – 
 
 
34 | P a g e  
 
Table 6. In silico ADMET screening results of protein kinase inhibitors. 
 
Ligand 
 
LogP 
 
LogSw 
 
HBonds 
 
Solubility 
(mg/l) 
Oral 
Bioavailability 
(VEBER) 
Oral 
Bioavailability 
(EGAN) 
 
Phospholipidosis 
 
Status 
 
CID 72271 
 
2.69 
 
-4.63 
 
8 
 
4692.41 
 
Good 
 
Good 
 
Noninducer 
 
Accepted 
 
CID 5287969 
 
3.25 
 
-4.49 
 
6 
 
4492.81 
 
Good 
 
Good 
 
Noninducer 
 
Accepted 
 
CID 4616292 
 
2.69 
 
-4.63 
 
8 
 
4692.41 
 
Good 
 
Good 
 
Noninducer 
 
Accepted 
 
CID 216239 
 
4.07 
 
-5.17 
 
7 
 
2648.90 
 
Good 
 
Good 
 
Noninducer 
 
Accepted 
 
CID 3499 
 
3.08 
 
-4.29 
 
7 
 
6078.39 
 
Good 
 
Good 
 
Noninducer 
 
Accepted 
 
CID 3843 
 
3.50 
 
-5.16 
 
8 
 
2850.94 
 
Good 
 
Good 
 
Noninducer 
 
Accepted 
 
CID 22386467 
 
4.48 
 
-4.96 
 
4 
 
2442.80 
 
Good 
 
Good 
 
Noninducer 
 
Accepted 
 
CID 123631 
 
4.11 
 
-4.89 
 
7 
 
3370.20 
 
Good 
 
Good 
 
Noninducer 
 
Accepted 
 
CID 5291 
(Control) 
 
3.52 
 
-4.92 
 
8 
 
3613.29 
 
Good 
 
Good 
 
Noninducer 
 
Accepted 
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Diferent properties of the compound are shown in tabular manner below: 
     
                           (a)                                            (b)                                                (c) 
Figure 19. 2D Structure of (a) CID 5287969 (b) CID 4616292 (c) CID 72271 
 
      
                         (a)                                               (b)                                                (c) 
Figure 20. PhysChem Filter Positioning of (a) CID 5287969 (b) CID 4616292 (c) CID 72271 
 
     
                        (a)                                                 (b)                                                (c) 
Figure 21. Compound Complexicity of (a) CID 5287969 (b) CID 4616292 (c) CID 72271 
36 | P a g e  
 
 
 
     
  
                         (a)                                                  (b)                                              (c) 
Figure 22. Pfizer 3/75 Rule Positioning of (a) CID 5287969 (b) CID 4616292 (c) CID 72271 
 
 
      
                        (a)                                                 (b)                                               (c) 
            Figure 23. Oral Property Space of (a) CID 4616292 (b) CID 72271 (c) CID 5287969 
 
 
        
                        (a)                                                (b)                                                 (c) 
Figure 24. Oral Absorption Estimation of (a) CID 5287969 (b) CID 4616292 (c) CID 72271 
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CHAPTER 6: CONCLUSION 
By analyzing the Molecular Docking results i.e, binding energies of all the inhibitory ligands, 
interactions of inhibitors with the receptor and the results from the ADMET studies, Alvocidib 
(CID 5287969) possesses promising inhibitory activity against BCR-ABL receptor. Hence, it 
can be concluded that Imatinib related protein kinase inhibitor Alvocidib can effectively inhibit 
the pathway initiated by BCR-ABL leading to CML. Again, Alvocidib can also prove to be a 
safe drug for oral medication. However, the results need to be validated by in vitro followed 
by clinical trials on CML patients. 
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